Come Together: OncoDxRx’s PGA and OncoMRD Close the Gap of Precision Medicine to Benefit Non-Responders Among the key weapons deployed by cancer cells, the heterogeneity was, along with the drug resistance, the most worrying for the clinicians. This highly dynamic malignancy had, in fact, the potential to profoundly transform the geometry of cancer combat, by considerably reducing the reaction times of modern Dx and Rx, while being almost invulnerable to the targeted therapy and immunotherapy existing today. OncoDxRx’s?aim is to strengthen our precision Dx capability. This will lead to “transformative technologies regarding specific solutions that will allow filling gaps, reducing costs and shortening implementation times”. PGA (patient-derived gene expression-informed anticancer drug efficacy) and OncoMRD (monitoring residual disease)?technologies are equipped with numerous innovations that allow them to demonstrate differentiating capabilities in precision oncology areas. OncoDxRx’s one-of-a-kind tests are able to guide treatment selection and monitor drug efficacy while remaining cost- and time-efficiency thanks to the automated and streamline workflow. The integration of state-of-the-art mRNA biomarkers and data analytics also gives them superior predictive power and surveillance, detection and tracking capabilities. PGA and OncoMRD are exclusive and disruptive technologies. They bring unmatched high quality gene expression profiles derived directly from patients. Finally, these technologies come with digital computation that facilitate the delivery of customized reports in 5 days. ? #opportunities?#strategy?#programming?#design?#team?#research?#data?#health?#development?#collaboration?#projects?#testing?#immunotherapy?#cancer?#technology?#biotechnology?#healthcare?#medicine?#oncology?#precisionmedicine?#liquidbiopsy?#rna?#dna?#venturecapital?#startup?#immunooncology?#tcells?#innovation?#growth?#tech?#lifesciences?#biopharma?#oncodxrx
OncoDxRx的动态
最相关的动态
-
Drug Efficacy Prediction Advances Could Transform Personalized Medicine “Cancer is a network-based disease driven by many interconnected components, but current machine learning and training models for predicting treatment responses don’t always reflect this. Rather than focusing on a few tumor genes or proteins, OncoDxRx’s PGA gene-to-drug technology evaluates the broader biochemical networks or pathways, both tumor and non-tumor microenvironment, vital for cancer killing." One cutting-edge of PGA is the combination of in vitro patient testing and in silico data computation that allows direct patient-to-drug bridging, also thanks to the much-reduced hand-on time and human error in the workflow.?This adds to data accuracy, which is also enhanced by the real-time patient testing, by cancer type-specific biomarkers, and by the patient-derived gene expression signature, which proved PGA’s effectiveness in the pilot real-world patient study.? #opportunities?#strategy?#programming?#design?#team?#research?#data?#health?#development?#collaboration?#projects?#testing?#immunotherapy?#cancer?#technology?#biotechnology?#healthcare?#medicine?#oncology?#precisionmedicine?#liquidbiopsy?#rna?#dna?#venturecapital?#startup?#immunooncology?#tcells?#innovation?#growth?#tech?#lifesciences?#biopharma?#oncodxrx
-
-
At OncoDxRx, we are dedicated to empowering precision medicine with cutting-edge solutions and outstanding performance. The newly released PGA technology seamlessly combines best-in-class in vitro transcriptomic profiling and in silico drug-mapping analytics in one integrated testing platform. PGA unlocks simultaneous measurement of a panel of circulating cell-free mRNA (cfmRNA) biomarkers at subcellular functional resolution from a single patient sample. “This revolutionary technique tells us how active a tumor is and could allow doctors to assess ALL existing cancer drugs in a patient to give a more holistic assessment of disease so the most appropriate treatment can be selected,” OncoDxRx said. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD?
-
-
PhD MBA | Empowering Innovation in Cell & Gene Therapy | AI/ML Driven Solutions for Sustainable Growth
Resharing Lonrú Consulting latest insights into the UK Cell and Gene Therapy (CGT) clinical trial landscape. The 2024 UK CGT Catapult report shows continued momentum in ongoing CGT clinical trials, but a notable 20% drop in new CGT trials started last year compared to 2023. To help make sense of the data, Lonrú has developed free interactive dashboards—offering a clear, structured view of clinical trial sponsors, phases, vector types, therapeutic areas, and locations. These are more than open data access —they’re designed to give a taste of what Lonrú can offer in terms of tailored, data-driven insights. ?? Check them out here: https://lnkd.in/eZtP3Kqn (Best viewed on a large screen for full usability!) For those working in CGT, biotech, or investment, let’s connect—I’d love to chat about how custom analytics can support your work. #CGT #ATMP #GeneTherapy #CellTherapy #ClinicalTrials #Biotech #LifeSciences #LonrúConsulting #DataDrivenInsights #Innovation
?? UK CGT Clinical Trials Report 2024 – Insights & Interactive Dashboards ???? The latest UK Cell and Gene Therapy Catapult ATMP Clinical Trials Report highlights a 7% increase in ongoing trials, reinforcing the UK’s position as a global leader in advanced therapies. Notably, 80% of these trials are commercially sponsored, and Oncology remains the dominant therapeutic area, with Metabolic diseases seeing the most growth. To help industry professionals explore the trends, sponsors, and trial activity, Lonrú Consulting has developed free, interactive dashboards—giving you deeper insights into trial phases, cell engineering methods, therapeutic areas, and sponsor activity. ?? Explore the dashboards here: https://lnkd.in/eRZs5Bxn ?? Key Highlights: ?? UCL tops the list as the leading sponsor of CGT trials, followed by Johnson & Johnson, with Vertex Pharmaceuticals and Great Ormond Street Hospital for Children NHS Foundation Trust in joint 3rd place. ?? Oncology accounts for 38% of trials, with metabolic indications seeing the most growth. ?? Gene therapy dominates, with an even split between in vivo and ex vivo approaches. At Lonrú Consulting, we’re committed to illuminating innovation in CGT. If you’d like to customise this dashboard for specific data needs or create bespoke analytics for your organisation, reach out—we’d love to collaborate. ?? Get in touch: [email protected] #CGT #ATMP #GeneTherapy #CellTherapy #ClinicalTrials #Biotech #LifeSciences #LonrúConsulting #Innovation #DataDrivenInsights
-
-
?? Key Trends from the 2025 J.P. Morgan Healthcare Conference ?? The 2025 J.P. Morgan Healthcare Conference (Jan 13-16) in San Francisco, highlighted exciting trends illustrating an industry rapidly evolving through new deals, technology integration and healthcare innovation: Strategic Partnerships. Mergers, acquisitions, and collaborations are on the rise with several major deals announced. Johnson & Johnson led the charge with a $14.6 billion acquisition of neuropsychiatric biotech Intra-Cellular Therapies. GSK also announced a $1 billion purchase of cancer drugmaker IDRx. These deals reflect the ongoing trend of companies working to strengthen their pipelines and enhance their competitive edge through strategic acquisitions. Biotech Innovation. Companies presented their latest developments in targeted therapies, immunotherapies, and precision medicine with a focus on cancer treatment.?Great hopes have arisen for cell and gene therapies with promising developments in the treatment of diseases like Type 1 Diabetes and Parkinson's disease. AI & Digital Health: AI was a major topic, with discussions on its impact on healthcare delivery and improve patient outcomes. Technology and AI are increasingly linked to biopharmaceuticals, revolutionizing drug discovery, diagnostics, and clinical decision-making. Leveraging reliable data is crucial to realize the full potential of AI in health care. The future of healthcare is rapidly evolving, driven by technological advances and collaboration. At EXTEND, we embrace these trends, focusing on expanding our network and portfolio with innovative projects aimed at developing novel therapies for a wide range of diseases. ?? Keep following us and learn more about EXTEND by visiting the website - https://extend-tt.vc/ ?#HealthcareInnovation #DigitalHealth #AI #Biotech #JPM2025
-
-
Although biomarker tests (or companion diagnostics) offer unprecedented capabilities, they ultimately qualify the minority of patients for precision medicine, while excluding the majority. Precision medicine can no longer solely count on superiority in the field of biomarker testing. PGA can gap-fill biomarker testing to complete test menu, but it is not a substitute or replacement. What is particularly great about PGA is that it provides clinicians with a new dimension of treatment selection. Currently, cancer patients had to be tested to be qualified for precision medicine, and the patient eligibility rate is at low end (around 20-30%) with an average response rate of 20-30%, and you do the math how many patients actually benefit from precision therapy?? With PGA patients now be able to benefit from more drug options than ever before. And because the technology is fitted with patient testing, gene activity detection, data mapping, drug matching and efficacy classification capabilities, as well as interfaces for data fusion, clinicians can be quickly notified of potentially effective drugs winning the decisive time for decision-making. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing
-
-
The Global Precision Medicine market is rapidly transforming healthcare, leveraging personalized treatment approaches tailored to individual genetic, environmental, and lifestyle factors. With a projected market value of over $200 billion by 2033, the sector is growing at a compound annual growth rate (CAGR) of approximately 15%. Key players in the market include major pharmaceutical companies like Roche, Novartis, and Pfizer, alongside biotechnology firms like Illumina, Thermo Fisher Scientific, and Guardant Health, all of which are at the forefront of innovation. Technological advancements such as next-generation sequencing (NGS) and bioinformatics tools are accelerating growth. The integration of Artificial Intelligence (AI) and machine learning in diagnostics and drug development is creating a more robust and precise framework for personalized treatments. Recent collaborations and acquisitions are enabling new therapeutic solutions, further fueling market expansion. Notable industry developments include the increasing adoption of liquid biopsy techniques and advanced gene therapies, marking a shift toward minimally invasive diagnostic tools. Liquid biopsy in precision oncology, a groundbreaking advancement, allows for non-invasive cancer detection through blood samples. This technology enables real-time monitoring of genetic mutations and tumor evolution, providing an effective tool for personalized cancer treatment. It holds immense potential for early cancer detection, reducing the need for traditional tissue biopsy procedures, and enabling better patient outcomes. As precision oncology continues to evolve, liquid biopsy is poised to become an integral part of cancer diagnostics, revolutionizing the way cancers are treated and managed. The market dynamics reflect an ongoing trend toward targeted therapies, regulatory advancements, and an increasing focus on patient-centric solutions. #PrecisionMedicine #LiquidBiopsy #Oncology #NextGenSequencing #PersonalizedHealthcare #Biotech #Genomics #AIinHealthcare #CancerCare #HealthcareInnovation #Pharma #MedTech #TargetedTherapies #Koncepo?
-
Strategy Consultant - Oncology | Driving Pharma & Biotech Growth | Custom Research & Consulting |
Is precision oncology killing more patients than it's saving? Shocking, I know. But hear me out... The latest market analysis reveals a disturbing trend: For almost every successful precision therapy, 3 others fail in late-stage trials. This isn't just burning through billions in R&D. It's burning through patient hope. Here's the kicker: 80% of these failures are due to poor biomarker strategy, not drug efficacy. We're chasing the wrong targets, folks. ?? The deep dive into the top 50+ #oncology pipelines shows: - 65% of companies are over-invested in "me-too" PD-1/PD-L1 inhibitors - Only 12+% are seriously exploring multi-omics approaches - A mere 5+% have robust real-world evidence programs The result? A #market saturated with lookalikes, while true innovation stagnates. But it's not all doom and gloom. The analysis identified 3 under-the-radar #biotechs poised to disrupt this pattern. Their secret? Integrating #AI with multi-omics for hyper-personalized trial design. Early results? Staggering. - 40+% reduction in trial failures - 60% improvement in patient outcomes - 2x faster time-to-market The oncology market is at a crossroads. Will you stick with the failing status quo? Or pivot to where the real breakthroughs are happening? The choice is yours. But choose fast. Because in this game, second place is just the first loser. Agree? Disagree? Let's debate. Drop your thoughts below ?? ??.??. ??????'?? ???????????? ???? ???????????? ?? ???????? ?????? ????????????. Let's shake up the industry together. #ColorectalCacner #Oncolyst
-
-
?????????????????????????????? ???????????????????? ?????????????????? ???????????????? ???? ???????????????? ???????? ??????????????'?? ????????????????????????????? ????????????? ???????????????????? We are transforming cancer care with our groundbreaking #3DTwin? Technology - a fully automated solution for testing patient-derived 3D microtumor models. By leveraging automation, decentralization, and standardization, we accelerate drug development and enrich personalized treatment decisions, making a real difference in the fight against cancer. ?????? ???? ?????? ???????????????????? ????????????????????????????? ?? ???????? ???????????????????? ?????? ?????????????????????? ?????? ??????????????????????: Automation is at the core of our technology, enabling us to scale processes while enhancing the quality and reliability of results. Automated workflows eliminate manual errors, ensuring consistent, standardized results and providing patients with quicker, more precise insights. ?? ???????????? ?????????????????????????? ?????????????? ????????????????????????????????: Our decentralized platform allows laboratories and clinics worldwide to seamlessly integrate our technology, bringing cutting-edge treatments directly to patients, regardless of location. ?? ??????????-?????? ????????????: Designed with simplicity in mind, our intuitive platform requires minimal interaction, accelerating adoption and eliminating training needs for researchers and medical professionals. ?? ?????????????? ????????????????, ?????????????????? ????????????????: Automating #3DTwin? assays reduces laboratory workload, boosts efficiency, and enhances test accuracy. Drug developers and clinicians can rely on consistent data to guide therapy choices, leading to better patient outcomes. With our #3DTwin? Technology, we're not just improving oncology workflows - we're revolutionizing them. ?????????? ???? ?????????????????? ???????????? ?????????????????? ????????????????? Discover how PreComb's #3DTwin? Technology can make a difference at www.precomb.com #3DTwinTechnology #InnovationLeaders #PrecisionMedicine #FunctionalPrecisionOncology #BetterPatientOutcomes #LabAutomation #InnoSuisse #Decentralization #Standardization #UserFriendly Olivier Mauti Peter Steiner Hal Bosher Micaela F. Freitas Misakyan Jens M. Kelm Kseniia Nikitina Severin Manser Patrick Aisher Anke Cassing Nathaniel Hutley
-
???????? ???????????? ?????????????????????? ????????????: ???????????????????? ?????? ?????????????????????????? ?????????? ???????????????? ???????? ????????????: https://lnkd.in/gY3rckub As we navigate through 2024, the ???????? ???????????? ?????????????????????? ???????????? continues to evolve, driven by innovation and a commitment to improving patient outcomes. Here’s a look at the key milestones shaping this vital sector: ???????? ???? ???????????? ???????????? The introduction of liquid biopsy technologies revolutionized early detection, allowing for non-invasive testing. This advancement significantly improved diagnosis accuracy and patient monitoring. ?????????????????? ???????????????????? ???? ???????????????? With a surge in funding, numerous biotech firms began developing next-generation sequencing (NGS) and biomarker identification tools. These efforts aimed to personalize treatment plans, enhancing efficacy and minimizing side effects. ?????????????????????? ???? ???? ?????? ?????????????? ???????????????? Artificial intelligence played a pivotal role in analyzing diagnostic data, leading to faster and more accurate results. Machine learning algorithms began assisting pathologists, reducing human error and streamlining workflows. ???????????? ???????????? ???????????? The lung cancer diagnostics market is projected to reach robust growth, driven by rising incidence rates and growing awareness. Key players are focusing on collaborations and partnerships to expand their diagnostic capabilities and reach underserved populations. ?????????????? ??????????: As we move forward, the emphasis will be on improving access to diagnostics globally and enhancing patient education. Together, we can make strides toward earlier detection and better outcomes for lung cancer patients. ?????? ??????????????: Roche Thermo Fisher Scientific Abbott QIAGEN Bio-Rad Laboratories Hologic, Inc. Siemens Healthineers Genomic Health Sysmex Corporation Agilent Technologies ???????????? ???????? ????????????: https://lnkd.in/gT5k-R-k Let’s continue to innovate and collaborate in this crucial field! #lungcancer #diagnostics #healthcareinnovation #biotech #patientcare #marketresearch #markettrends #businessinsights #globalindustry
-
-
Manager - Advisory | Ex- Deloitte, Ex - Trianz, Ex - Gati | Strategic Advisory | Consulting | Research Specialist
Precision medicine is transforming healthcare by tailoring treatments to individual genetic profiles. Our latest study dives deep into its market growth, challenges, and opportunities—ushering in a new era of personalized care. Read more here: [https://lnkd.in/d-3J6P4F] #PrecisionMedicine #HealthcareInnovation #LifeSciences #SectorInsights #LiquidBiopsy #Oncology #NextGenSequencing #PersonalizedHealthcare #Biotech #Genomics #AIinHealthcare #CancerCare #HealthcareInnovation #Pharma #MedTech #TargetedTherapies #Koncepo
The Global Precision Medicine market is rapidly transforming healthcare, leveraging personalized treatment approaches tailored to individual genetic, environmental, and lifestyle factors. With a projected market value of over $200 billion by 2033, the sector is growing at a compound annual growth rate (CAGR) of approximately 15%. Key players in the market include major pharmaceutical companies like Roche, Novartis, and Pfizer, alongside biotechnology firms like Illumina, Thermo Fisher Scientific, and Guardant Health, all of which are at the forefront of innovation. Technological advancements such as next-generation sequencing (NGS) and bioinformatics tools are accelerating growth. The integration of Artificial Intelligence (AI) and machine learning in diagnostics and drug development is creating a more robust and precise framework for personalized treatments. Recent collaborations and acquisitions are enabling new therapeutic solutions, further fueling market expansion. Notable industry developments include the increasing adoption of liquid biopsy techniques and advanced gene therapies, marking a shift toward minimally invasive diagnostic tools. Liquid biopsy in precision oncology, a groundbreaking advancement, allows for non-invasive cancer detection through blood samples. This technology enables real-time monitoring of genetic mutations and tumor evolution, providing an effective tool for personalized cancer treatment. It holds immense potential for early cancer detection, reducing the need for traditional tissue biopsy procedures, and enabling better patient outcomes. As precision oncology continues to evolve, liquid biopsy is poised to become an integral part of cancer diagnostics, revolutionizing the way cancers are treated and managed. The market dynamics reflect an ongoing trend toward targeted therapies, regulatory advancements, and an increasing focus on patient-centric solutions. #PrecisionMedicine #LiquidBiopsy #Oncology #NextGenSequencing #PersonalizedHealthcare #Biotech #Genomics #AIinHealthcare #CancerCare #HealthcareInnovation #Pharma #MedTech #TargetedTherapies #Koncepo?
